MDMB-CHMINACA

MDMB-CHMINACA
Systematic (IUPAC) name
	Methyl 2-{[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate
Clinical data
Legal status	CA: Schedule II;
Identifiers
CAS Number	1185888-32-7
ChemSpider	32055574
Chemical data
Formula	C22H31N3O3
Molecular mass	385.5 g/mol
	SMILES COC(=O)C(C(C)(C)C)NC(=O)c1nn(c2c1cccc2)CC1CCCCC1 ;
	InChI InChI=1S/C22H31N3O3/c1-22(2,3)19(21(27)28-4)23-20(26)18-16-12-8-9-13-17(16)25(24-18)14-15-10-6-5-7-11-15/h8-9,12-13,15,19H,5-7,10-11,14H2,1-4H3,(H,23,26) ; Key:DGQMLBSSRFFINY-UHFFFAOYSA-N ;

MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB₁ receptor and has been sold online as a designer drug.^[1]^[2]^[3]^[4] It is closely related to MDMB-FUBINACA, which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.^[5]

Legal status

MDMB-CHMINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.^[6]

MDMB-CHMINACA is illegal in Switzerland as of December 2015.^[7]

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.